COMPANY

Kovina Therapeutics

HQ: Indianapolis, IN source · kovina.com ↗ · Midwest

Keywords: oncology infectious disease

Location: Indianapolis, IN · source · Oct 15, 2026

Profile checked Oct 10, 2026

NIH awards 6

Annual award amounts. Total $4.0M.

Aug 14, 2026 NIH award 1R44CA302154-01A1 FY2026: $1,143,891 awarded for that fiscal year; activity R44 (SBIR); PI RIETZ, ANNE; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. Novel Therapeutics to Treat HPV-Asso source ↗
Apr 1, 2024 NIH award 5R44CA268137-03 FY2024: $1,000,028 awarded for that fiscal year; activity R44 (SBIR); PI RIETZ, ANNE; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. From Academia to Business: Development source ↗
Apr 27, 2023 NIH award 4R44CA268137-02 FY2023: $909,657 awarded for that fiscal year; activity R44 (SBIR); PI RIETZ, ANNE; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. From Academia to Business: Development o source ↗
Aug 11, 2022 NIH award 1R43DE031495-01A1 FY2022: $275,766 awarded for that fiscal year; activity R43 (SBIR); PI LU, ZHIJIAN; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. Small Molecule E6 Inhibitors to Treat source ↗
Jun 30, 2022 NIH award 1R43AI167573-01 FY2022: $298,527 awarded for that fiscal year; activity R43 (SBIR); PI LU, ZHIJIAN; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. Small Molecule E6 Inhibitors to Treat Dy source ↗
Feb 25, 2022 NIH award 1R42CA268137-01 FY2022: $420,989 awarded for that fiscal year; activity R42 (STTR); PI RIETZ, ANNE; recipient as written: KOVINA THERAPEUTICS INC., INDIANAPOLIS, IN. From Academia to Business: Development o source ↗

NIH award NIH awarded $1.14M (SBIR Phase II 1R44CA302154-01A1, new, notice Aug 14, 2026). NIH RePORTER 1R44CA302154-01A1 (Aug 14, 2026)
Evidence (1 event)
- Aug 14, 2026 · NIH RePORTER 1R44CA302154-01A1
  Organization: KOVINA THERAPEUTICS INC.; City/State: INDIANAPOLIS, IN; Project number: 1R44CA302154-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1143891; Administering IC: National Cancer Institute; Project title: Novel Therapeutics to Treat HPV-Associated Cancers; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals